8,990 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Aster Capital Management DIFC Ltd

Aster Capital Management DIFC Ltd bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, Holdings Channel reports. The firm bought 8,990 shares of the medical device company’s stock, valued at approximately $699,000.

A number of other hedge funds also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new stake in shares of DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA boosted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares in the last quarter. TD Private Client Wealth LLC grew its holdings in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC grew its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter valued at $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DXCM. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Citigroup upped their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley upped their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Finally, Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares of the company’s stock, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Jon Brown sold 13,000 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $59.83 on Friday. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $141.99. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a 50 day moving average price of $80.14 and a 200 day moving average price of $76.92. The company has a market cap of $23.46 billion, a price-to-earnings ratio of 41.84, a PEG ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.